Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 1 minute read Healthcare Industry News Sorrento Therapeutics acquires majority stake in Zhengzhou FortuneBio Sorrento Therapeutics has acquired a majority stake in Zhengzhou Fortune Bioscience (Zhengzhou FortuneBio), a Chinese diagnostic manufacturer, for… byPallavi MadhirajuFebruary 20, 2022
